{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60","upperLimit":"92","value":"71"},{"groupId":"OG001","lowerLimit":"36","upperLimit":"91","value":"57"}]}],"title":"Global Health Status"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92","upperLimit":"225","value":"128"},{"groupId":"OG001","lowerLimit":"57","upperLimit":"106","value":"67"}]}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"120","upperLimit":"259","value":"146"},{"groupId":"OG001","lowerLimit":"57","upperLimit":"124","value":"85"}]}],"title":"Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57","upperLimit":"85","value":"58"},{"groupId":"OG001","lowerLimit":"46","upperLimit":"67","value":"57"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86","upperLimit":"147","value":"92"},{"groupId":"OG001","lowerLimit":"62","upperLimit":"337","value":"85"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92","upperLimit":"155","value":"127"},{"groupId":"OG001","lowerLimit":"67","upperLimit":"141","value":"106"}]}],"title":"Disease Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78","upperLimit":"123","value":"90"},{"groupId":"OG001","lowerLimit":"58","upperLimit":"113","value":"85"}]}],"title":"Side Effects of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"123","upperLimit":"338","value":"225"},{"comment":"Could not be calculated due to a low number of events","groupId":"OG001","lowerLimit":"85","upperLimit":"NA","value":"162"}]}],"title":"Health Utility"}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"Time to worsening in quality of life domains was calculated as the time from Baseline to the first worsened minimally important difference (MID), defined as the smallest change in a QOL score considered important to patients that would lead the patient or clinician to consider a change in therapy. MID thresholds were calculated in Standard Error of Measurement (SEM) units using the Baseline QOL data. Based on the MID, participants were classified as worsened according to the following: For the EORTC QLQ-C30 global health status and functional scales and the EQ-5D health utility score, participants were classified as worsened if their change from Baseline score was less than -1 SEM. For the EORTC QLQ-C30 symptom scores (fatigue and pain) and EORTC QLQ-MY20 disease symptoms and side effects scales, participants were classified as worsened if their change from Baseline score was greater than 1 SEM. See previous outcome measures for definitions of each scale.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Low-Dose Dexamethasone"},{"description":"Participants received 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression.","id":"OG001","title":"High-Dose Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"PRO population","reportingStatus":"POSTED","timeFrame":"Assessed on Day 1 of the first 6 treatment cycles.","title":"Time to First Worsening of Quality of Life (QOL) Domains","type":"SECONDARY","unitOfMeasure":"days"}